Vascular Sealant Market Report 2026

The vascular sealant market size has grown strongly in recent years. It will grow from $1.71 billion in 2025 to $1.85 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to rising number of surgical procedures, increasing prevalence of cardiovascular diseases, advancements in surgical technologies, growing demand for effective hemostasis solutions, expansion of healthcare infrastructure.

The vascular sealant market size is expected to see strong growth in the next few years. It will grow to $2.51 billion by 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to increasing adoption of minimally invasive surgeries, rising demand for advanced biomaterials, growing investment in surgical innovation, expansion of outpatient surgical centers, increasing focus on patient safety and faster recovery. Major trends in the forecast period include increasing adoption of advanced hemostatic agents in surgeries, rising preference for minimally invasive surgical sealants, growing demand for fast-acting and high-strength vascular sealants, development of bioresorbable and biocompatible sealant materials, expansion of multi-application sealants across surgical specialties.

The increasing prevalence of cardiovascular disease is expected to drive the growth of the vascular sealant market going forward. Cardiovascular disease refers to a group of disorders that affect the heart and blood vessels, including conditions such as ischemic heart disease and stroke. The prevalence of cardiovascular diseases is rising due to population aging and growth, along with increased exposure to risk factors such as obesity, diabetes, high blood pressure, poor diet, sedentary lifestyles, and smoking, which collectively elevate the risk of heart and blood vessel disorders. Vascular sealants help manage cardiovascular disease by enabling effective control of bleeding, supporting vascular repair, and reducing complications during surgical procedures. For instance, according to the Scottish Health Survey 2024 by the Scottish Government, a Scotland-based government administration, 16% of adults reported living with any cardiovascular disease (CVD), with prevalence increasing from 4% among individuals aged 16-24 to 42% among adults aged 75 and over. Therefore, the rising prevalence of cardiovascular disease is driving the growth of the vascular sealant market.

Leading companies operating in the vascular sealant market are focusing on leveraging innovative technologies such as grip technology to achieve faster hemostasis and improved patient recovery. Grip technology, a hydrophilic polymer-based system, forms a secure and flexible seal at the vascular access site, helping achieve rapid hemostasis, minimizing the risk of bleeding complications, reducing patient recovery time, and enabling earlier ambulation and discharge, while providing a minimally invasive alternative to traditional manual compression methods. For example, in July 2024, Cordis Corporation, a US-based medical device company, received U. S. Food and Drug Administration (FDA) approval for the Mynx Control Venous VCD, an innovative device that leverages Grip Technology based on hydrophilic, bioinert polyethylene glycol. The Mynx Control Venous VCD provides effective closure for midbore venous puncture sites, including those used in electrophysiology procedures, and demonstrated 100% procedural and device success in clinical trials. Key benefits include significantly reduced time to hemostasis (2.1 minutes versus 11.4 minutes for manual compression), faster amb.

In January 2026, Haemonetics Corporation, a US-based medical technology company, acquired Vivasure Medical Limited for an undisclosed consideration. With this acquisition, Haemonetics seeks to broaden its portfolio of large-bore vascular closure devices, strengthen its technological capabilities in minimally invasive vascular procedures, accelerate innovation in structural heart and endovascular therapies, and expand its global customer base in interventional cardiology and vascular surgery. Vivasure Medical Limited is an Ireland-based medical technology company specializing in the development of vascular sealant.

Major companies operating in the vascular sealant market are Johnson & Johnson, Pfizer Inc., Medtronic plc, Stryker Corporation, Becton Dickinson and Company, Baxter International Inc., B. Braun Melsungen AG, Grifols S. A., Terumo Corporation, Teleflex Incorporated, Integra LifeSciences Holdings Corporation, CSL Behring LLC, Advanced Medical Solutions Group plc, SkinStitch Inc., Tricol Biomedical Inc., Cellphire Therapeutics Inc., Artivion Inc., GluStitch Inc., CuraMedical B. V., Endomedix Inc.

North America was the dominating region in the vascular sealant market in 2025. Asia-Pacific is expected to be the rapidly expanding region during the forecast period. The regions covered in the vascular sealant market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the vascular sealant market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vascular sealant market consists of sales of polyethylene glycol sealants, cyanoacrylate adhesives, albumin-based sealants, collagen-based hemostatic sealants, thrombin-based sealants, gelatin-based sealants, bioabsorbable vascular sealants, hemostatic patches, surgical sealant applicators, dual syringe delivery systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.